Trials / Completed
CompletedNCT03005678
Denosumab Versus Bisphosphonates (Alendronate) in GIOP
Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Tuen Mun Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A randomized controlled trial to compare for the efficacy and tolerability of denosumab and oral alendronate in the management of glucocorticoid induced osteoporosis
Detailed description
Study design: an open-label randomized controlled trial Duration of study: 12 months Treatment arms: 1. Denosumab: a total of 2 doses in a period of 12 months 2. Oral alendronate: weekly dose in a period of 12 months Target sample size: 220 patients (110 patients in each arm)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Denosumab | active treatment group |
| DRUG | Alendronate | comparator |
Timeline
- Start date
- 2017-04-01
- Primary completion
- 2019-11-01
- Completion
- 2020-02-01
- First posted
- 2016-12-29
- Last updated
- 2020-02-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03005678. Inclusion in this directory is not an endorsement.